Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Skin Neoplasms 1Melanoma 1

Interventions

Nivolumab 3Niacinamide 2HhAntag691 2urelumab 1pembrolizumab 1fludarabine phosphate 1fludarabine 1encorafenib 1cemiplimab 1binimetinib 1avelumab 1aldesleukin 1X-Rays 1Vitamin A 1Tranexamic Acid 1Sunscreening Agents 1Niacin 1Mohs Surgery 1Itraconazole 1Ipilimumab 1Interleukin-2 1Influenza Vaccines 1Indocyanine Green 1Immune Checkpoint Inhibitors 1Exercise 1Dimethyl Sulfoxide 1Cyclophosphamide 1Biopsy 1Ascorbic Acid 1Aminolevulinic Acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Skin Neoplasms × urelumab × Clear all
NCT02652455 2025-08-19

Combining PD-1 Blockade, CD137 Agonism and Adoptive Cell Therapy for Metastatic Melanoma

H. Lee Moffitt Cancer Center and Research Institute

Phase EARLY_PHASE1 Completed
11 enrolled
Dermatologic

Melanoma, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡